Hypoxia in Prostate Cancer: Correlation of BOLD-MRI With Pimonidazole Immunohistochemistry-Initial Observations

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 4, 2007, Pages 1065-1071

  Hoskin, Peter J ^a   Carnell, Dawn M ^a   Taylor, N Jane ^a   Smith, Rowena E ^a   Stirling, J James ^a   Daley, Frances M ^a   Saunders, Michele I ^a   Bentzen, Søren M ^b   Collins, David J ^c   d'Arcy, James A ^c   Padhani, Anwar P ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

BOLD MRI; DCE MRI; Hypoxia; Prostate carcinoma

Indexed keywords

HISTOLOGIC PROTOCOLS; HYPOXIA; PROSTATE CARCINOMA; PROSTATECTOMY;

DIAGNOSIS; MEDICAL IMAGING; NONINVASIVE MEDICAL PROCEDURES; PATIENT MONITORING; TUMORS;

MAGNETIC RESONANCE IMAGING;

CONTRAST MEDIUM; PIMONIDAZOLE;

ADULT; AGED; ARTICLE; BLOOD VOLUME; CANCER SURGERY; CELL HYPOXIA; CELL SPECIFICITY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGING; IMMUNOHISTOCHEMISTRY; MALE; MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN BLOOD LEVEL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TISSUE OXYGENATION; TUMOR LOCALIZATION;

AGED; CELL HYPOXIA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NITROIMIDAZOLES; OXYGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; STAINING AND LABELING;

EID: 34447261183     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.01.018     Document Type: Article

References (12)

1. Adams G.E. The clinical relevance of tumour hypoxia. Eur J Cancer 26 (1990) 420-421
2. Padhani A.R., Harvey C.J., and Cosgrove D.O. Angiogenesis imaging in the management of prostate cancer. Nat Clin Pract Urol 2 (2005) 596-607
3. Hoskin P.J., Sibtain A., Daley F.M., et al. The role of GLUT1 and CAIX as intrinsic immunohistochemical markers of hypoxia and predictors of outcome after radiotherapy for bladder carcinoma. Br J Cancer 89 (2003) 1290-1297
4. Alonzi R., and Hoskin P. Novel therapies in bladder cancer. Clin Oncol 17 (2005) 524-538
5. Alonzi R., and Hoskin P.J. Functional imaging in clinical oncology: Magnetic resonance imaging- and computerised tomography-based techniques. Clin Oncol (R Coll Radiol) 18 (2006) 555-570
6. Howe F.A., Robinson S.P., McINtyre D.J., et al. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 14 (2001) 497-506
7. d'Arcy J.A., Collins D.J., Padhani A.R., et al. Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: Analysis and visualization of dynamic contrast-enhanced MR imaging data. Radiographics 26 (2006) 621-632
8. Raleigh J.A., Chou S.C., Arteel G.E., et al. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 151 (1999) 580-589
9. Carnell D.M., Smith R.E., Daley F.M., et al. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance. Int J Radiat Oncol Biol Phys 665 (2006) 91-99
10. Padhani AR, Krohn KA, Lewis JS, et al. Imaging oxygenation of human tumours. Eur Radiol. In press.
11. Claus F.G., Hricak H., and Hattery R.R. Pretreatment evaluation of prostate cancer: Role of MR imaging and 1H MR spectroscopy. Radiographics 24 Suppl. 1 (2004) S167-S180
12. van Lin E.N., Futterer J.J., Heijmink S.W., et al. IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 65 (2006) 291-303